Ovimox 1 mg/ml Oral Solution for Sheep

Care should be taken to avoid the following practices because they increase the
risk of development of resistance and could ultimately result in ineffective therapy:
- Too frequent and repeated use of anthelmintics from the same class, over an
extended period of time
- Underdosing, which may be due to underestimation of body weight,
misadministration of the product, or lack of calibration of the dosing device (if any).
Suspected clinical cases of resistance to anthelmintics should be further
investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test).

Revised: March 2026
AN: 04331/2025
Where the results of the test(s) strongly suggest resistance to a particular
anthelmintic, an anthelmintic belonging to another pharmacological class and
having a different mode of action should be used.
Resistance to macrocyclic lactones has been reported in Teladorsagia in sheep in
a number of countries. In 2019, throughout Europe, moxidectin resistance is very
rare; it has been reported in a case involving a levamisole-, benzimidazole- and
ivermectin-resistant strain of Teladorsagia circumcincta
ivermectin-resistant strain of T. circumcincta. Therefore the use of this product
should be based on local (regional, farm) epidemiological information about
susceptibility of parasites, local history of treatments and recommendations on
how to use the product under sustainable conditions to limit further selection for
resistance to antiparasitic compounds. These precautions are especially important
when moxidectin is being used to control resistant strains.

Special precautions for use in animals
None known.
Special precautions to be taken by the person administering the veterinary
medicinal product to animals
This product can cause skin and eye irritation.
Avoid direct contact with skin and eyes.
Wear impermeable rubber gloves during use.
In the event of eye contact, flush the eye with copious amounts of clean water and
seek medical advice.
Wash hands after use.
Do not smoke or eat when using this product.
Other precautions regarding impact on the environment
Moxidectin fulfils the criteria for a (very) persistent, bioaccumulative and toxic
(PBT) substance; therefore, exposure of the environment to moxidectin must be
limited to the extent possible. Treatments should be administered only when

Revised: March 2026
AN: 04331/2025
necessary and should be based on faecal egg counts or evaluation of the risk of
infestation at the animal and/or herd level.
Like other macrocyclic lactones, moxidectin has the potential to adversely affect
non-target organisms:
•
may temporarily reduce the abundance of dung feeding organisms.
Following treatment of sheep with the product, levels of moxidectin that
are potentially toxic to dung fly species may be excreted over a period of
4 days and may decrease dung fly abundance during that period. It has
been established in laboratory tests that moxidectin may temporarily
affect dung beetle reproduction; however, studies with incurred residues
indicate no long-term effects. Nevertheless, in case of repeated
treatments with moxidectin (as with products of the same anthelmintic
class) it is advisable not to treat animals every time on the same pasture
to allow dung fauna populations to recover.
•
product should be used only according to the label instructions. Based on
the excretion profile of moxidectin when administered as the oral
formulation to sheep, treated animals should not have access to
watercourses during the first 3 days after treatment.